WEBULL
WebtradeDownload

Is Rocket Lab (RKLB) Fully Priced Following Its ESCAPADE Mars Mission Milestone?

Simply Wall St · 2d ago

Rocket Lab (RKLB) stock is reacting to a very specific catalyst. The company has just confirmed that its twin ESCAPADE spacecraft successfully executed trans Mars injection burns, sending NASA’s Mars mission firmly on its way.

Rocket Lab’s latest Mars success comes during a busy period for the stock. It has just logged a 7 day share price return of 26.31% after a softer 90 day share price move that declined 17.42%. The 1 year total shareholder return of 32.38% and very large 3 year total shareholder return suggest longer term momentum has been strong, even as recent trading has been choppy around Q3 losses, Neutron delays and the pending Iridium deal.

Spot fresh space plays riding similar contract momentum as Rocket Lab by scanning our hand picked 87 robotics and automation stocks that is powering next generation missions and orbital infrastructure.

Rocket Lab now appears to be a mission capable business with deep space credentials and a substantial contract backlog. After a sharp bounce and a low value score, the question is whether the current share price reflects that story too generously or not generously enough.

Most Popular Narrative: 22% Overvalued

Rocket Lab closed at $66.15, while the most followed narrative on the stock puts fair value closer to $54.43, so the community view sketches in a premium that readers need to understand in context. According to DanielOliveira, an investor in the Simply Wall St Community who built this narrative, the short term setup around earnings and margins is the key swing factor.

The swing factor inside the quarter is launch. All six Electron launches in Q3 were missions booked on launch day. Q2 also had six, but two were HASTE flights whose revenue was mostly booked earlier, so launch revenue fell to $44.6 million. On Q3's mix I get about $59.8 million. Space Systems was $189.5 million in Q2, and with the first full quarters of Mynaric and Motiv I get about $200 million.

See why 5 investors see Rocket Lab as 22% overvalued.

Result: Fair Value of $54.43 (OVERVALUED)

Still, two obvious pressure points could flip that overvaluation story: Q4 guidance falling short of expectations and Neutron contract timing slipping against the backlog.

Find out about the key risks to this Rocket Lab narrative.

Rocket Lab: A Very Different Valuation Story On Cash Flows

The community narrative tags Rocket Lab as 22% overvalued at a fair value of $54.43, yet the SWS DCF model points in the opposite direction. On that cash flow view, the stock at $66.15 trades about 41% below an estimate of $111.76. This frames the same business as materially undervalued. Which lens should carry more weight for you: a near term narrative around margins, or a longer horizon view built on future cash flows?

To understand how the SWS DCF model arrives at that gap between price and estimated value, Look into how the SWS DCF model arrives at its fair value.

RKLB Discounted Cash Flow as at Nov 2026
RKLB Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Rocket Lab for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages in the Rocket Lab story so far. Use that tension as a prompt to move quickly, scrutinize the numbers yourself, and weigh both the upside potential and the areas that worry other investors with the help of 2 key rewards and 3 important warning signs

Hunting For More Ideas Beyond Rocket Lab?

Do not stop at Rocket Lab. Broaden your watchlist with a few focused screens that surface very different types of opportunities across the market.